People ex rel. Strathmann v. Acacia Research Corp.

210 Cal. App. 4th 487, 148 Cal. Rptr. 3d 361, 2012 Cal. App. LEXIS 1105
CourtCalifornia Court of Appeal
DecidedOctober 24, 2012
DocketNo. G045390
StatusPublished
Cited by48 cases

This text of 210 Cal. App. 4th 487 (People ex rel. Strathmann v. Acacia Research Corp.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
People ex rel. Strathmann v. Acacia Research Corp., 210 Cal. App. 4th 487, 148 Cal. Rptr. 3d 361, 2012 Cal. App. LEXIS 1105 (Cal. Ct. App. 2012).

Opinion

Opinion

FYBEL, J.

Introduction

The anti-SLAPP statute,1 Code of Civil Procedure section 425.16 (section 425.16), authorizes a special motion to strike “[a] cause of action against a person arising from any act of that person in furtherance of the person’s right of petition or free speech under the United States Constitution or the California Constitution in connection with a public issue.” (§ 425.16, subd. (b)(1).) Code of Civil Procedure section 425.17, subdivision (b) (section 425.17(b)) creates an exception to the anti-SLAPP statute for any action “brought solely in the public interest or on behalf of the general public” if three conditions set forth in the statute are met. Such a public interest lawsuit is not subject to a special motion to strike under section 425.16.

A qui tarn action2 is one brought under a statute that allows a private person to sue as a private attorney general to recover damages or penalties, [492]*492all or part of which will be paid to the government.. (People ex rel. Allstate Ins. Co. v. Weitzman (2003) 107 Cal.App.4th 534, 538 [132 Cal.Rptr.2d 165] (Weitzman).) Under California law, a qui tam action is brought on behalf of the People of the State of California, and the People are “ ‘[t]he real party in interest.’ ” (Ibid.; see U.S. ex rel. Killingsworth v. Northrop Corp. (9th Cir. 1994) 25 F.3d 715, 720.)

In this case, we conclude the qui tam action brought by Michael Strathmann as relator “on behalf of the general public” under Insurance Code section 1871.7 falls within the public interest exception of section 425.17(b). The trial court erred by finding otherwise and should have denied the special motion to strike brought by defendants Acacia Research Corporation (Acacia), CombiMatrix Corporation (CombiMatrix), and Amit Kumar (collectively, Defendants). We therefore reverse the order granting Defendants’ special motion to strike, reverse the order and judgment awarding Defendants attorney fees and costs, and remand.

Allegations of the Complaint

Strathmann’s qui tam complaint against Acacia, CombiMatrix, and Kumar alleged the following facts.

I.

Theft of Technology Developed at Nanogen, Inc.

Acacia, a publicly owned Delaware corporation, formed CombiMatrix in 1995 as a subsidiary. In 2007, CombiMatrix separated from Acacia and became a publicly traded company. Kumar joined Acacia as a vice-president in 2000 and the next year became the chief executive officer of CombiMatrix, a position he held until the end of June 2010.

In 1994, Dr. Donald Montgomery went to work for Nanogen, Inc. (Nanogen), a biotechnology company in San Diego. Montgomery signed an agreement with Nanogen, which provided that any invention conceived by Montgomery while at Nanogen belonged to it. While employed by Nanogen, Montgomery invented a unique biotechnology process by which chemical compounds were made on an array of electrodes. Montgomery disclosed his new invention to Brooke Anderson, one of Acacia’s founders, and conspired with Acacia to start a biotechnology company based upon the new invention. Acacia made at least one payment to Montgomery while he was employed by Nanogen.

Montgomery resigned from Nanogen in August 1995. In October 1995, he and Acacia founded a new company, CombiMatrix, to commercially exploit [493]*493this “stolen technology.” Montgomery continued to receive additional payments from Acacia through Anderson.

In November 1995, Montgomery sued Nanogen over rights to the technology he developed at Nanogen. In February 1996, Nanogen and Montgomery settled the lawsuit.

In April 1996, Montgomery became a director of CombiMatrix and received shares of its stock. In July 1996, he filed a provisional patent application covering CombiMatrix’s core technology. This patent application was based upon the invention that Montgomery had conceived while at Nanogen.

n.

Nanogen’s Lawsuit Against CombiMatrix and Montgomery

In November 2000, Nanogen filed a lawsuit alleging CombiMatrix and Montgomery had stolen technology owned by Nanogen. In December 2000, Acacia and CombiMatrix notified National Union Fire Insurance Company of Pittsburgh, Pennsylvania (National Union), of the Nanogen lawsuit, and made a claim under Acacia’s directors, officers and corporate liability policy (the Policy) issued by National Union. The Policy required National Union to reimburse certain defense costs over a self-insured retention. National Union acknowledged receipt of the claim and sent a letter to CombiMatrix, addressing policy issues and requesting more information.

When Nanogen filed its lawsuit, CombiMatrix was in the early stages of negotiating a transaction to customize and license its technology to Roche Applied Science (Roche). Roche was concerned about the Nanogen lawsuit and throughout 2001 expressed concern whether CombiMatrix had clear title to the technology.

In April and September 2001, CombiMatrix requested that National Union reimburse legal expenses incurred in the Nanogen lawsuit. National Union did not respond in writing to either request.

Several weeks into the litigation, CombiMatrix began to look for ways to settle with Nanogen. CombiMatrix wanted to settle the lawsuit because Montgomery had stolen the technology from Nanogen, its lawsuit was an impediment to CombiMatrix going public, and Roche wanted CombiMatrix to secure clear title to the technology before providing it with additional funding. CombiMatrix’s efforts to settle the Nanogen lawsuit were not related [494]*494to any alleged failure of National Union to reimburse legal expenses, and CombiMatrix’s March 2002 revised financial forecast made no mention of any cash shortage caused by that lawsuit.

Roche required the effective date of its agreement with CombiMatrix be the date that CombiMatrix settled the Nanogen litigation. A draft partnership document required that CombiMatrix obtain a settlement with Nanogen, by which Nanogen would confirm CombiMatrix’s sole ownership of some disputed patents.

In July 2002, while preparing for production of documents to Nanogen, CombiMatrix’s attorneys discovered the check written by Acacia to Montgomery while he was employed by Nanogen. Kumar later described this check as a “smoking gun.”

III.

Settlement of the Nanogen Lawsuit

On August 8, 2002, CombiMatrix reached agreement in principle to settle with Nanogen. As of that date, CombiMatrix had not communicated with National Union for over a year. A new claims representative at National Union sent a letter to CombiMatrix, asking about the status of the Nanogen lawsuit. CombiMatrix did not respond.

On September 30, 2002, CombiMatrix entered into a final written settlement agreement with Nanogen. CombiMatrix agreed to pay Nanogen cash, stock, and future royalties with a total value of $20.1 million. On the same day, Kumar informed Roche executives that the Nanogen lawsuit had been settled and the condition to the Roche agreement was satisfied.

In late 2002, Strathmann, who was then an employee of CombiMatrix, asked Kumar why the Nanogen lawsuit had been settled for such a large percentage of CombiMatrix stock.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Byrne v. Rule
California Court of Appeal, 2025
Byrne v. Rule CA2/6
California Court of Appeal, 2025
Howard Jarvis Taxpayers Assn. v. Powell CA4/2
California Court of Appeal, 2024
Odette Batis v. Dun & Bradstreet Holdings, Inc.
106 F.4th 932 (Ninth Circuit, 2024)
Kim Martinez v. Zoominfo Technologies, Inc.
82 F.4th 785 (Ninth Circuit, 2023)
Truong v. Tran CA4/3
California Court of Appeal, 2023
Flate v. Nationstar Mortgage CA2/3
California Court of Appeal, 2023
Heitkoetter v. Domm
E.D. California, 2022
Mohamad v. X-Therma, Inc.
N.D. California, 2022
Xu v. Huang
California Court of Appeal, 2022
Xu v. Huang CA2/1
California Court of Appeal, 2021
Becerra v. The McClatchy Co.
California Court of Appeal, 2021
Exline v. Gillmor
California Court of Appeal, 2021
State v. Abbvie Inc.
390 F. Supp. 3d 1176 (N.D. California, 2019)
MMM Holdings, Inc. v. Reich
California Court of Appeal, 2018
MMM Holdings, Inc. v. Reich
230 Cal. Rptr. 3d 198 (California Court of Appeals, 5th District, 2018)
P. ex rel. etc. v. Hebb
California Court of Appeal, 2017

Cite This Page — Counsel Stack

Bluebook (online)
210 Cal. App. 4th 487, 148 Cal. Rptr. 3d 361, 2012 Cal. App. LEXIS 1105, Counsel Stack Legal Research, https://law.counselstack.com/opinion/people-ex-rel-strathmann-v-acacia-research-corp-calctapp-2012.